Comparing outcomes after open and endovascular chronic mesenteric ischemia revascularization –10-year single-center experience
DOI:
https://doi.org/10.48750/acv.634Keywords:
Chronic intestinal ischemia, superior mesenteric artery, open mesenteric revascularization, endovascular mesenteric revascularizationAbstract
INTRODUCTION: Chronic mesenteric ischemia (CMI) is a rare but life-threatening disease. This study aimed to analyze the safety and effectiveness of open (OR) and endovascular (ER) revascularization and respective outcomes in a consecutive series of CMI patients.METHODS: From 2013 to 2023, all CMI patients treated with OR and ER were retrospectively identified. Demographics, comorbidities, clinical presentation, preoperative imaging, and revascularization modalities were analyzed. Patients were grouped according to the type of revascularization (OR and ER) and compared for the study’s endpoints. The primary endpoint was the reintervention rate, and the secondary endpoints were overall survival and reintervention-free survival.
RESULTS: Thirty-three patients with CMI (60% male, mean age 67, range 45-88 years) were treated by ER (27 patients) or OR (6 patients). The median follow-up was 38 (9-72) months. The ER of the superior mesenteric artery (SMA) included the deployment of covered balloon-expandable stents in 85 % (n=23) of the patients. The OR included SMA bypass using prosthetic conduit and iliac artery inflow in 83 % (n=5) of the patients. Long SMA lesions (>20mm) were present in 100 % of the OR group patients and 44 % of the patients in the ER group (p=.027). Reintervention due to symptom recurrence and target artery restenosis or re-occlusion was performed in four patients in the ER group, of which one patient underwent open surgery and three underwent endovascular surgery. The three-year reintervention rate was 18% in the ER and 0% in the OR group (p=.374). Thirty-day and 3-year overall survival in the OR and ER groups were 67% vs. 93% and 44% vs. 87%, respectively (p=.015). Three-year reintervention-free survival in the OR and ER groups was 50 % vs. 70%, respectively (p=.103).
CONCLUSIONS: According to this study, we should expect lower survival in CMI patients who undergo OR, probably related to the higher burden of atherosclerotic disease observed in this group. However, the improved survival observed after ER is offset by a trend towards higher reintervention rates.
Downloads
References
Conrad MF, Chronic mesenteric ischemia: epidemiology, pathophysiology, clinical evaluation and management. In: Sidaway AN, Perler BA, Vascular Surgery and Endovascular Therapy. Elsevier; 2023:1760-1778.
Clair DG, Beach JM. Mesenteric Ischemia. N Engl J Med. 2016;374:959-68.
Menges AL, Reutersberg B, Busch A, Salvermoser M, Feith M, Trenner M, et al. Early and Midterm Outcomes of Open and Endovascular Revascularization of Chronic Mesenteric Ischemia. World J Surg. 2020;44:280-412.
Huber TS, Björck M, Chandra A, Clouse WD, Dalsing MC, Oderich GS, Chronic mesenteric ischemia: Clinical practice guidelines from the Society for Vascular Surgery. J Vasc Surg. 2021;73:875-185.
Björck M, Koelemay M, Acosta S, Bastos Goncalves F, Kölbel T, Kolkman JJ, et al. Editors' Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017;53:460-510.
Kayssi A, Al-Atassi T, Oreopoulos G, Roche-Nagle G, Tan KT, Rajan DK. Drug-sluting balloon angioplasty versus unceased balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2016;2016:CD01319.
Oderich GS, Erdoes LS, Lesar C, Mendes BC, Gloviczki P, Cha S, et al. Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease. J Vasc Surg. 2013;58:1316-23.
Terlowu LG, van Dijk LJD, van Noord D, Bakker CJ, Bijdewaate DC, Erler NS, et al. Covered versus bare-metal stenting of the mesenteric arteries in patients with chronic mesenteric ischemia (CoBad): a multicentre, patient-blinded and investigator-blinded, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:299-309.
Zacharias N, Ephabella SD, Chang BB, Kreienberg PB, Roddy SP, Taggert JB, et al. Chronic mesenteric ischemia outcome analysis and predictors of endovascular failure. J Vasc Surg. 2016;63:1582-7.
Shamurthy N, Rhodes JM, Lee D, Waldman DL, Green RM, Davies MG. Endovascular versus open mesenteric revascularization: immediate benefits do not equate with short-term functional outcomes. J Am Coll Surg. 2006;202:859-67.
Arya S, Kingman S, Knapper JP, Eliason JL, Henke PK, Rectenwald JE. Open Mesenteric Interventions Are Equally Safe as Endovascular Interventions and Offer Better Midterm Patency for Chronic Mesenteric Ischemia. Ann Vasc Surg. 2016;30:219-26.
Oderich GS, Gloviczki P, Bower TC. Open surgical treatment for chronic mesenteric ischemia in the endovascular era: when it is necessary and what is the preferred technique?. Semin Vasc Surg. 2010;23:36-46.
van Petersen AS, Kolkman JJ, Beuk RJ, Huisman AB, Doelman CJ, Geelkerken RH. Open or percutaneous revascularization for chronic splanchet syndrome. J Vasc Surg. 2010;51:1309-16.
Kasirajan K, O'Hara PJ, Gray BH, Hertzer NR, Clair DG, Greenberg RK et al. Chronic mesenteric ischemia: open surgery versus percutaneous angioplasty and stenting. J Vasc Surg. 2001;33:637-1.
Silva JA, White CJ, Collins TJ, Jenkins JS, Andry ME, Reilly JP et al. Endovascular therapy for chronic mesenteric ischemia. J Am Coll Cardiol. 2006;47:944-50.
Deck MA, Conrad MF, Kwolek CJ, LaMuraglia GM, Paruchuri V, Cambria RP. Intermediate-term outcomes of endovascular treatment for symptomatic chronic mesenteric ischemia. J Vasc Surg. 2010;51:40-7.
Tallarita T, Oderich GS, Gloviczki P, Duncan AA, Kalra M, Cha S, et al. Patient survival after open and endovascular mesenteric revascularization for chronic mesenteric ischemia using propensity score-matched comparison. J Vasc Surg. 2013;57:747-55.
